Computational design and immunoinformatic validation of a multistage mRNA vaccine candidate against Mycobacterium tuberculosis
In Silico Pharmacology · 20.06.2026 · 14 (2)
DOI: 10.1007/s40203-026-00675-8 ↗Kurz gefasst
Fachartikel in der Zeitschrift In Silico Pharmacology, online erschienen am 20.06.2026. Verfasst von Manika Sharma und 6 weiteren Autor:innen. Beteiligte Einrichtung: DSKC BioDiscovery Laboratory, Miranda House, University of Delhi, New Delhi, Delhi 110007 India. Die Arbeit nennt 113 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Tuberculosis (TB), the biggest cause of death from any known infectious disease, has been a problem for the world’s health system for many years. The only approved vaccine is BCG and now a number of vaccines are undergoing clinical trials. The newly recognised mRNA vaccines can provide a good alternative to the traditional vaccine. Therefore, the goal of this work is to use computational techniques to build a multi-stage tuberculosis mRNA vaccine. Nine multistage-expressing Mycobacterium tuberculosis (Mtb) proteins that have been linked to cell entry, pathogenesis, and dormancy regulon were used. Eighteen promiscuous, proinflammatory, non-toxic antigenic epitopes that bound to both MHC classes (I and II) were chosen from nine proteins. Co-translational structural components (5′m7G cap, UTRs, Kozak sequence, Poly A tail) were incorporated into the design of the mRNA vaccine, which was predicted to be stable. Additionally, molecular docking reveals the vaccine candidate’s interaction with TLR2 and TLR4 immunological receptors by establishing a Leucine-Rich-Repeats (LRR) specific interface. Molecular dynamics (MD) simulations were also performed to evaluate the structural stability and dynamical behaviour of the vaccine candidate in complex with TLR2 and TLR4. Following the simulations, binding free energy calculations were conducted using the Molecular Mechanics/Poisson–Boltzmann Surface Area (MM/PBSA) method, which indicated stable thermodynamic binding of the vaccine candidate with both the receptors. Immune simulation tests using C-Immsim predicted that the translated vaccine construct was immunogenic and showed population coverage of 99.98%. Overall, it was anticipated that this multi-stage expressing mRNA vaccine would be highly immunogenic, stable, safe, and antigenic. Our approach to develop an immunoinformatics-based mRNA vaccine appears promising against tuberculosis; nonetheless, experimental confirmation is required.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- DSKC BioDiscovery Laboratory, Miranda House, University of Delhi, New Delhi, Delhi 110007 India.
- Present Address: Center for Infection and Inflammation Imaging Research, Johns Hopkins University School of Medicine, Baltimore, MD USA.
- Computational Biophysics and CADD Group, Computational and Mathematical Biology Centre (CMBC), BRIC-Translational Health Science and Technology Institute, Faridabad, Haryana 121001 India.
Zitieren
APA
Sharma, M., Bhatt, P., Singh, M., Lokhande, K. B., Asthana, S., Sharma, M., & Sharma, S. (2026). Computational design and immunoinformatic validation of a multistage mRNA vaccine candidate against Mycobacterium tuberculosis. In Silico Pharmacology, 14(2). https://doi.org/10.1007/s40203-026-00675-8
Vancouver
Sharma M, Bhatt P, Singh M, Lokhande KB, Asthana S, Sharma M, et al. Computational design and immunoinformatic validation of a multistage mRNA vaccine candidate against Mycobacterium tuberculosis. In Silico Pharmacology. 2026;14(2). doi:10.1007/s40203-026-00675-8
BibTeX
@article{Sharma2026,
author = {Sharma, Manika and Bhatt, Parul and Singh, Medha and Lokhande, Kiran Bharat and Asthana, Shailendra and Sharma, Monika and Sharma, Sadhna},
title = {Computational design and immunoinformatic validation of a multistage mRNA vaccine candidate against Mycobacterium tuberculosis},
journal = {In Silico Pharmacology},
year = {2026},
volume = {14},
number = {2},
doi = {10.1007/s40203-026-00675-8}
}
EUVIMED